Background
Methods
Study design and setting
-
Participant registered after a single-dose PI or after the third COVID-19 vaccination: 14 days (short-term survey), 40 days (long-term survey), and 124 days (follow-up survey) after vaccination.
-
Participant registered after the first dose of a two-dose PI: 14 days (short-term survey) and 40 days (long-term survey) after the first and second vaccination as well as 124 (follow-up survey) days after the first vaccination.
-
Participant registered after the second dose of a two-dose PI: 14 days (short-term survey) and 40 days (long-term survey) after the second vaccination as well as 124 (follow-up survey) days after the first vaccination.
Sample size calculation
Surveys
-
First dose: BNT162b2; mRNA-1273; ChAdOx1; Ad26.COV2-S
-
Second dose regimens: homologous: BNT162b2 − BNT162b2; mRNA-1273 − mRNA-1273; ChAdOx1 − ChAdOx1; heterologous: ChAdOx1 − BNT162b2; ChAdOx1 − mRNA-1273
-
Booster regimens: PI with BNT162b2 or mRNA-1273 (PI mRNA) + BNT162b2; PI mRNA + mRNA-1273; PI with ChAdOx1 (PI vector) + BNT162b2; PI vector + mRNA-1273; PI with BNT162b2 or mRNA-1273 and ChAdOx1 (PI mRNA/vector) + BNT162b2; PI mRNA/vector + mRNA-1273
Statistical analysis
Results
Sociodemographic characteristics
After first vaccination
Comparison of vaccines
|
After second vaccination
Comparison of vaccination regimens
|
After third vaccination
Comparison of vaccination regimens
| |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
mRNA
|
Vector
|
Homologous mRNA
|
Homologous vector
|
Heterologous
|
Homologous PI mRNA
|
Homologous PI vector
|
Heterologous PI mRNA/vector
| ||||||||
Short-term survey
| |||||||||||||||
BNT | m1273 | ChAd | Ad26 | BNT- BNT | m1273 m1273 | ChAd- ChAd | ChAd-BNT | ChAd-m1273 | BNT | m1273 | BNT | m1273 | BNT | m1273 | |
N
|
2044
|
687
|
177
|
155
|
5391
|
1386
|
439
|
1098
|
820
|
884
|
782
|
84
|
59
|
204
|
229
|
Gender (%) | |||||||||||||||
Female | 55.9 | 62.6 | 36.7 | 41.3 | 57.6 | 60.2 | 41.2 | 59.5 | 59.8 | 62.8 | 56.0 | 45.2 | 44.1 | 60.3 | 38.9 |
Male | 44.0 | 37.1 | 63.3 | 58.7 | 42.3 | 39.5 | 58.8 | 40.5 | 40.2 | 37.1 | 44.0 | 54.8 | 55.9 | 39.7 | 61.1 |
Divers | 0 | 0.3 | 0 | 0 | 0.1 | 0.3 | 0 | 0 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | 0 |
Age
| |||||||||||||||
Mean | 42.1 | 41.4 | 46.1 | 39.2 | 44.8 | 43.4 | 56.3 | 48.3 | 47.5 | 38.1 | 47.3 | 51.9 | 51.1 | 40.1 | 51.9 |
SD | 14.8 | 14.4 | 15.9 | 12.9 | 15.3 | 14.4 | 15.6 | 13.9 | 13.9 | 16.4 | 11.4 | 15.8 | 12.7 | 14.3 | 12.9 |
No pre-existing diseases (%) | |||||||||||||||
44.8 | 44.7 | 48.0 | 60.0 | 40.0 | 42.3 | 29.6 | 36.7 | 42.1 | 47.3 | 41.4 | 36.9 | 40.7 | 53.4 | 48.5 | |
m-SCQ-D
| |||||||||||||||
Median | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IQR | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–3 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–1 | 0–2 |
BMI
| |||||||||||||||
Mean | 25.4 | 25.7 | 25.2 | 25.1 | 25.8 | 25.8 | 26.9 | 25.8 | 25.8 | 24.7 | 25.9 | 25.7 | 28.7 | 25.1 | 26.1 |
SD | 5.4 | 5.4 | 4.3 | 4.0 | 5.4 | 5.4 | 5.2 | 5.0 | 5.3 | 5 | 5.1 | 5.1 | 5.4 | 5.4 | 4.6 |
NA | 27 | 16 | 3 | 1 | 62 | 22 | 5 | 12 | 8 | 10 | 8 | 1 | 0 | 2 | 2 |
Participants with other vaccinations 8 weeks before first/third vaccination (%) | |||||||||||||||
5.8 | 4.8 | 7.9 | 3.2 | 5.5 | 5.2 | 5.5 | 5.9 | 7.1 | 25.7 | 25.7 | 41.7 | 32.2 | 35.8 | 33.6 | |
Time between 1st and 2nd vaccination (days) | |||||||||||||||
Mean | 40.2 | 41.6 | 76.6 | 68.6 | 75.9 | ||||||||||
SD | 5.8 | 3.2 | 12.8 | 13.1 | 11.4 | ||||||||||
NA | 62 | 22 | 5 | 12 | 8 | ||||||||||
Long-term survey
| |||||||||||||||
BNT | m1273 | ChAd | Ad26 | BNT- BNT | m1273 m1273 | ChAd- ChAd | ChAd-BNT | ChAd-m1273 | mRNA PI-BNT | mRNA PI-m1273 | Vector PI-BNT | Vector PI-m1273 | Het. PI-BNT | Het. PI-m1273 | |
N
|
2002
|
689
|
192
|
159
|
5513
|
1378
|
426
|
1201
|
847
|
932
|
829
|
92
|
61
|
226
|
233
|
Gender (%) | |||||||||||||||
Female | 56.0 | 61.4 | 37.0 | 42.1 | 58.1 | 60.7 | 41.3 | 61.5 | 60.9 | 62.6 | 56.0 | 45.7 | 49.2 | 63.7 | 38.6 |
Male | 44.0 | 38.5 | 63.0 | 57.9 | 41.8 | 39.0 | 58.7 | 38.5 | 39.0 | 37.2 | 44.0 | 54.3 | 50.8 | 36.3 | 61.4 |
Divers | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.3 | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Age
| |||||||||||||||
Mean | 44.6 | 41.7 | 48.4 | 39.7 | 45.1 | 43.9 | 57.3 | 48.5 | 48.4 | 38.4 | 47.6 | 51.7 | 50.8 | 40.3 | 51.9 |
SD | 15.3 | 14.4 | 16.2 | 12.9 | 15.3 | 14.5 | 15.6 | 13.5 | 14.1 | 16.3 | 11.3 | 15.8 | 13.0 | 14.1 | 13.0 |
No pre-existing diseases (%) | |||||||||||||||
40.0 | 44.1 | 42.2 | 61.0 | 39.8 | 41.4 | 30.0 | 37.1 | 41.8 | 47.6 | 41.4 | 37.0 | 44.3 | 52.2 | 46.8 | |
m-SCQ-D
| |||||||||||||||
Median | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
IQR | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–3 | 0–2 | 0–1 | 0–2 | 0–2 | 0–2 | 0–2 | 0–1 | 0–1,5 |
BMI
| |||||||||||||||
Mean | 25.8 | 25.8 | 25.6 | 25.2 | 25.8 | 25.8 | 26.6 | 25.8 | 25.8 | 24.9 | 26.0 | 26.0 | 28.4 | 25.2 | 26.3 |
SD | 5.6 | 5.4 | 4.6 | 4.2 | 5.4 | 5.4 | 5.2 | 5.1 | 5.3 | 5.2 | 5.2 | 5.1 | 5.3 | 5.6 | 4.9 |
NA | 28 | 13 | 2 | 1 | 64 | 22 | 5 | 10 | 7 | 10 | 8 | 1 | 0 | 3 | 2 |
Participants with other vaccinations 8 weeks before first vaccination (%) | |||||||||||||||
5.7 | 4.6 | 7.3 | 3.1 | 5.5 | 5.3 | 4.9 | 6.2 | 7.3 | 25.4 | 26.7 | 42.4 | 27.9 | 35.8 | 32.2 | |
Time between 1st and 2nd vaccination (days) | |||||||||||||||
Mean | 40.2 | 41.5 | 76.6 | 68.6 | 75.9 | ||||||||||
SD | 5.8 | 3.2 | 12.8 | 13.1 | 11.4 | ||||||||||
NA | 7 | 1 | 0 | 1 | 0 | ||||||||||
Follow-up survey
| |||||||||||||||
BNT | m1273 | ChAd | Ad26 | BNT- BNT | m1273 m1273 | ChAd- ChAd | ChAd-BNT | ChAd-m1273 | mRNA PI-BNT | mRNA PI-m1273 | Vector PI-BNT | Vector PI-m1273 | Het. PI-BNT | Het. PI-m1273 | |
N
|
5539
|
1342
|
471
|
1382
|
879
|
916
|
796
|
94
|
60
|
207
|
233
| ||||
Gender (%) | |||||||||||||||
Female | 58.8 | 61.2 | 41.0 | 61.9 | 60.4 | 63.3 | 55.8 | 47.9 | 46.7 | 66.7 | 38.6 | ||||
Male | 41.1 | 38.5 | 59.0 | 38.1 | 39.5 | 36.6 | 44.2 | 52.1 | 52.3 | 33.3 | 61.4 | ||||
Divers | 0.1 | 0.4 | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
Age
| |||||||||||||||
Mean | 45.6 | 44.6 | 57.3 | 48.9 | 48.4 | 39.0 | 47.8 | 52.0 | 50.8 | 40.9 | 51.9 | ||||
SD | 15.2 | 14.3 | 15.4 | 13.6 | 14.3 | 16.6 | 11.4 | 15.9 | 12.6 | 14.0 | 13.0 | ||||
No pre-existing diseases (%) | |||||||||||||||
38.9 | 39.9 | 29.9 | 37.4 | 41.9 | 46.8 | 41.2 | 36.2 | 43.3 | 50.7 | 45.9 | |||||
m-SCQ-D
| |||||||||||||||
Median | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
IQR | 0–2 | 0–2 | 0–3 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | ||||
BMI
| |||||||||||||||
Mean | 25.8 | 25.9 | 26.8 | 25.6 | 25.9 | 24.9 | 26.0 | 25.7 | 28.2 | 25.0 | 26.2 | ||||
SD | 5.4 | 5.4 | 5.3 | 4.9 | 5.2 | 5.2 | 5.1 | 5.3 | 5.2 | 5.2 | 4.9 | ||||
NA | 59 | 21 | 6 | 14 | 1 | 10 | 8 | 1 | 0 | 3 | 2 | ||||
Participants with other vaccinations 8 weeks before first vaccination (%) | |||||||||||||||
7.2 | 4.8 | 5.1 | 6.2 | 7.3 | 26.3 | 26.6 | 40.4 | 26.7 | 37.2 | 33.5 | |||||
Time between 1st and 2nd vaccination (days) | |||||||||||||||
Mean | 40.2 | 41.6 | 76.8 | 70.5 | 77.8 | ||||||||||
SD | 6 | 3.8 | 13 | 12.9 | 10.9 | ||||||||||
NA | 6 | 0 | 0 | 0 | 0 |
Descriptive results of the short-term survey
First vaccination
Second vaccination
Third vaccination
Descriptive results of the long-term and follow-up surveys
After first vaccination
Comparison of vaccines
|
After second vaccination
Comparison of vaccination regimens
| ||||||||||||||
mRNA
|
Vector
|
Homologous mRNA
|
Homologous vector
|
Heterologous
| |||||||||||
BNT | 1273 | ChAd | Ad26 | BNT - BNT | 1273 – 1273 | ChAd - ChAd | ChAd - BNT | ChAd - 1273 | |||||||
LT | LT | LT | LT | LT | FU | LT | FU | LT | FU | LT | FU | LT | FU | ||
N
|
2002
|
689
|
192
|
159
|
5513
|
5539
|
1378
|
1342
|
426
|
471
|
1201
|
1382
|
847
|
879
| |
Participants with SARS-CoV-2 infection after vaccination (%) | |||||||||||||||
0.6 | 0.0 | 0.5 | 1.3 | 0.5 | 1.3 | 0.4 | 0.7 | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | ||
NA (n) | 9 | 2 | 1 | 1 | 14 | 1 | 1 | 0 | 0 | 1 | 6 | 6 | 4 | 4 | |
Medical consultation (%) | |||||||||||||||
Doctor’s consultation | 11.0 | 11.2 | 15.1 | 12.0 | 12.8 | 19.4 | 13.7 | 18.3 | 13.4 | 15.9 | 14.0 | 15.8 | 13.3 | 14.0 | |
Doctor’s consultation in planning | 1.8 | 2.5 | 1.0 | 4.4 | 2.4 | 2.6 | 2.7 | 3.0 | 1.2 | 2.1 | 2.6 | 2.5 | 2.2 | 2.2 | |
Hospital care | 1.6 | 1.3 | 2.6 | 0.6 | 1.7 | 2.5 | 1.1 | 2.2 | 2.6 | 2.5 | 1.1 | 1.1 | 0.7 | 1.1 | |
Hospital care in planning | 0.0 | 0.1 | 0.0 | 1.3 | 0.1 | 0.4 | 0.4 | 0.3 | 0.2 | 0.2 | 0.1 | 0.4 | 0.0 | 0.0 | |
Participants with at least one medical consultation
| |||||||||||||||
% | 13.0 | 13.8 | 16.7 | 16.5 | 15.4 | 21.4 | 16.5 | 21.6 | 14.8 | 18.3 | 16.8 | 18.4 | 15.7 | 16.4 | |
n
|
261
|
95
|
32
|
26
|
849
|
1183
|
227
|
290
|
63
|
86
|
203
|
254
|
133
|
144
| |
Thereof:
| |||||||||||||||
HPlMC was unknown to the participant (%) | |||||||||||||||
All HPlMC | 48.7 | 45.3 | 68.8 | 46.2 | 51.0 | 51.8 | 57.3 | 54.1 | 50.8 | 43.0 | 53.7 | 49.2 | 56.4 | 56.9 | |
At least one | 35.2 | 35.8 | 31.2 | 38.5 | 35.9 | 34.5 | 35.7 | 32.4 | 33.3 | 36.0 | 30.0 | 34.3 | 31.6 | 28.5 | |
Participant suspected association of HPlMC to vaccination (%) | |||||||||||||||
Regarding all HPlMC | 5.0 | 12.6 | 3.1 | 7.7 | 4.6 | 2.9 | 6.6 | 3.8 | 1.6 | 3.5 | 4.9 | 2.8 | 5.3 | 4.2 | |
Regarding at least on HPlMC | 23.0 | 17.9 | 18.8 | 23.1 | 21.9 | 17.7 | 30.8 | 19.7 | 17.5 | 10.5 | 16.7 | 16.1 | 18.8 | 18.1 | |
All HPlMC unknown and association with vaccination is suspected by the participant (%) | |||||||||||||||
4.2 | 9.4 | 3.1 | 7.6 | 3.9 | 2.4 | 5.7 | 2.8 | 1.6 | 2.3 | 4.4 | 2.4 | 5.3 | 4.2 | ||
Health problems leading to medical consultation (%) | |||||||||||||||
Musculoskeletal disorders | 36.8 | 49.5 | 34.3 | 41.9 | 39.9 | 40.3 | 43.5 | 38.3 | 49.1 | 48.7 | 38.4 | 38.9 | 38.3 | 38.2 | |
General symptoms | 42.5 | 52.6 | 31.2 | 38.1 | 42.8 | 41.9 | 57.2 | 46.9 | 34.8 | 29.0 | 33.0 | 31.5 | 33.1 | 36.1 | |
Neurological disorders | 36.4 | 44.2 | 37.4 | 34.3 | 32.4 | 29.2 | 43.1 | 30.7 | 39.6 | 26.7 | 31.5 | 26.0 | 34.6 | 29.8 | |
Cardiovascular disorders | 19.2 | 9.5 | 18.7 | 15.2 | 17.7 | 15.7 | 15.0 | 14.1 | 17.4 | 16.2 | 8.4 | 10.2 | 17.3 | 13.2 | |
Unsolicited health problems | 52.5 | 55.8 | 56.1 | 45.7 | 51.6 | 48.9 | 45.7 | 48.0 | 53.8 | 54.5 | 53.2 | 46.8 | 57.9 | 56.9 | |
No health problem named | 6.5 | 6.3 | 6.2 | 3.8 | 5.4 | 4.7 | 19.4 | 4.1 | 3.2 | 3.5 | 6.4 | 6.7 | 4.5 | 4.2 | |
After third vaccination: Comparison of vaccination regimens
| |||||||||||||||
Homologous primary immunisation mRNA
|
Homologous primary immunisation vector
|
Heterologous primary immunisation mRNA/vector
| |||||||||||||
BNT | 1273 | BNT | 1273 | BNT | 1273 | ||||||||||
LT | FU | LT | FU | LT | FU | LT | FU | LT | FU | LT | FU | ||||
N
|
932
|
916
|
829
|
796
|
92
|
94
|
61
|
60
|
226
|
207
|
233
|
233
| |||
Participants with COVID-19 infection after vaccination (%, no missing values) | |||||||||||||||
2.4 | 26.0 | 1.9 | 22.2 | 1.1 | 23.4 | 0.0 | 23.3 | 1.8 | 24.6 | 1.7 | 24.5 | ||||
Medical consultation (%) | |||||||||||||||
Doctor’s consultation | 13.4 | 29.9 | 13.6 | 29.8 | 18.5 | 30.9 | 8.2 | 25.0 | 11.9 | 26.6 | 12.4 | 24.9 | |||
Doctor’s consultation in planning | 3.8 | 1.6 | 2.5 | 2.0 | 2.2 | 0.0 | 1.6 | 1.7 | 1.8 | 0.5 | 2.1 | 2.1 | |||
Hospital care | 1.3 | 2.7 | 1.6 | 2.3 | 5.4 | 4.3 | 0.0 | 3.3 | 1.8 | 3.9 | 0.9 | 2.1 | |||
Hospital care in planning | 0.3 | 0.1 | 0.4 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | |||
Participants with at least one medical consultation
| |||||||||||||||
% | 17.4 | 31.7 | 16.9 | 32.3 | 20.7 | 31.9 | 9.8 | 26.7 | 13.7 | 29.5 | 14.6 | 27.5 | |||
n
|
162
|
290
|
140
|
257
|
19
|
30
|
6
|
16
|
31
|
61
|
34
|
64
| |||
Thereof:
| |||||||||||||||
HPiMC was unknown to the participant (%) | |||||||||||||||
All HPlMC | 48.1 | 50.3 | 55.0 | 56.0 | 52.6 | 70.0 | 33.3 | 43.8 | 51.6 | 55.7 | 47.1 | 60.9 | |||
At least one | 34.6 | 36.2 | 32.9 | 33.9 | 31.6 | 20.0 | 16.7 | 25.0 | 32.3 | 29.5 | 26.5 | 28.1 | |||
Participant suspected association of HPlMC to vaccination (%) | |||||||||||||||
Regarding all HPlMC | 2.5 | 2.4 | 0.0 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 6.5 | 1.6 | 2.9 | 0.0 | |||
Regarding at least on HPlMC | 16.7 | 10.3 | 18.6 | 14.8 | 10.5 | 13.3 | 33.3 | 6.2 | 12.9 | 6.6 | 2.9 | 0.0 | |||
All HPlMC unknown and association with vaccination is suspected by the participant (%) | |||||||||||||||
1.8 | 2.1 | 0.0 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 6.5 | 1.6 | 2.9 | 0.0 | ||||
Health problems leading to medical consultation (%) | |||||||||||||||
Musculoskeletal disorders | 35.8 | 41.7 | 36.4 | 35.8 | 26.3 | 33.3 | 33.5 | 25.0 | 38.8 | 44.2 | 26.5 | 29.7 | |||
General symptoms | 40.1 | 48.9 | 40.7 | 54.5 | 36.8 | 43.4 | 50.2 | 43.7 | 42.0 | 52.4 | 38.2 | 56.2 | |||
Neurological disorders | 25.9 | 31.0 | 33.5 | 32.7 | 21.0 | 30.0 | 33.5 | 31.2 | 35.5 | 29.5 | 23.5 | 25.0 | |||
Cardiovascular disorders | 21.6 | 16.5 | 15.7 | 18.3 | 5.3 | 10.0 | 16.7 | 6.2 | 12.9 | 13.1 | 8.8 | 6.2 | |||
Unsolicited health problems | 47.5 | 39.3 | 43.5 | 48.6 | 47.3 | 53.4 | 66.9 | 56.2 | 51.7 | 49.1 | 47.0 | 39.0 | |||
No health problem named | 3.1 | 6.2 | 7.9 | 2.7 | 5.3 | 0.0 | 0.0 | 6.2 | 6.5 | 1.6 | 5.9 | 3.1 |
Multivariate regression analyses of local and systemic reactions reported in the short-term surveys
First vaccination
Second vaccination
Local reactions 14
days after the vaccination
|
Systemic reactions 14
days after the vaccination
| |||||||
---|---|---|---|---|---|---|---|---|
OR
|
95% CI
|
p-value
|
OR
|
95% CI
|
p-value
| |||
LL | UL | LL | UL | |||||
First vaccination (n
= 3060, reference = BNT162b2)
| ||||||||
Intercept | 3.01 | 2.28 | 3.85 | < 0.0001 | 1.82 | 1.40 | 2.35 | < 0.0001 |
mRNA-1273 | 2.05 | 1.69 | 2.51 | < 0.0001 | 1.48 | 1.24 | 1.78 | < 0.0001 |
ChAdOx1 | 1.10 | 0.80 | 1.53 | 0.5536 | 6.41 | 4.31 | 9.80 | < 0.0001 |
Ad26.COV2-S | 0.68 | 0.49 | 0.96 | 0.0278 | 4.21 | 2.86 | 6.36 | < 0.0001 |
Age | 0.97 | 0.97 | 0.98 | < 0.0001 | 0.97 | 0.97 | 0.98 | < 0.0001 |
Female | 2.09 | 1.79 | 2.44 | < 0.0001 | 1.80 | 1.54 | 2.10 | < 0.0001 |
mSCQ | 1.05 | 0.99 | 1.10 | 0.0878 | 1.19 | 1.13 | 1.25 | < 0.0001 |
Interval V-R | 1.01 | 0.99 | 1.04 | 0.3121 | 1.03 | 1.01 | 1.05 | 0.0153 |
Second vaccination (n
= 9124, reference = BNT162b2 + BNT162b2)
| ||||||||
Intercept | 3.46 | 2.65 | 4.52 | < 0.0001 | 7.05 | 5.28 | 9.44 | < 0.0001 |
mRNA-1273 − mRNA-1273 | 3.10 | 2.68 | 3.59 | < 0.0001 | 3.80 | 3.23 | 4.48 | < 0.0001 |
ChAdOx1 − ChAdOx1 | 0.57 | 0.42 | 0.76 | 0.0019 | 1.13 | 0.83 | 1.55 | 0.4262 |
ChAdOx1 − BNT162b2 | 1.49 | 1.19 | 1.88 | 0.0057 | 2.97 | 2.31 | 3.85 | < 0.0001 |
ChAdOx1 − mRNA-1273 | 3.18 | 2.40 | 4.22 | < 0.0001 | 5.57 | 4.06 | 7.69 | < 0.0001 |
Age | 0.97 | 0.97 | 0.97 | < 0.0001 | 0.97 | 0.96 | 0.97 | < 0.0001 |
Female | 2.12 | 1.93 | 2.32 | < 0.0001 | 1.98 | 1.80 | 2.18 | < 0.0001 |
mSCQ | 1.09 | 1.06 | 1.12 | < 0.0001 | 1.12 | 1.09 | 1.16 | < 0.0001 |
Interval V-R | 1.01 | 1.00 | 1.01 | < 0.0001 | 1.01 | 1.01 | 1.01 | < 0.0001 |
Interval to 2nd dose | 1.00 | 0.99 | 1.00 | 0.379 | 0.99 | 0.98 | 1.00 | 0.0059 |
Third vaccination (n
= 2241, reference = PI mRNA + BNT162b2)
| ||||||||
Intercept | 2.32 | 1.72 | 3.14 | < 0.0001 | 3.37 | 2.48 | 4.59 | < 0.0001 |
PI mRNA + mRNA-1273 | 2.33 | 1.87 | 2.91 | < 0.0001 | 2.48 | 1.98 | 3.10 | < 0.0001 |
PI vector + BNT162b2 | 1.08 | 0.67 | 1.73 | 0.7605 | 0.87 | 0.54 | 1.41 | 0.5810 |
PI vector + mRNA-1273 | 1.27 | 0.73 | 2.20 | 0.3991 | 1.87 | 1.07 | 3.34 | 0.0293 |
PI mRNA/vector + BNT162b2 | 1.07 | 0.78 | 1.47 | 0.6678 | 1.41 | 1.02 | 1.96 | 0.0408 |
PI mRNA/vector + mRNA-1273 | 1.82 | 1.32 | 2.51 | 0.0003 | 1.87 | 1.36 | 2.59 | 0.0001 |
Age | 0.97 | 0.97 | 0.98 | < 0.0001 | 0.96 | 0.96 | 0.97 | < 0.0001 |
Female | 1.98 | 1.66 | 2.38 | < 0.0001 | 1.69 | 1.41 | 2.03 | < 0.0001 |
mSCQ | 1.10 | 1.04 | 1.17 | 0.0015 | 1.13 | 1.06 | 1.20 | 0.0002 |
Interval V-R | 1.01 | 0.98 | 1.04 | 0.5416 | 1.05 | 1.02 | 1.08 | 0.0016 |
Third vaccination
Multivariate regression analyses of medical consultations reported in the long-term and follow-up surveys
Long-term survey — first vaccination
OR | 95% CI |
p-value
| OR | 95% CI |
p-value
| |||
---|---|---|---|---|---|---|---|---|
LL | UL | LL | UL | |||||
Long-term survey:
Doctor’s consultation
|
Long-term survey:
Hospital care
| |||||||
First vaccination (n = 3038, reference = BNT162b2)
| ||||||||
Intercept | 0.11 | 0.07 | 0.16 | < 0.0001 | 0.01 | 0.00 | 0.04 | < 0.0001 |
mRNA-1273 | 1.16 | 0.89 | 1.50 | 0.2785 | 1.03 | 0.47 | 2.07 | 0.9368 |
ChAdOx1 | 1.65 | 1.07 | 2.47 | 0.0189 | 2.16 | 0.72 | 5.28 | 0.1223 |
Ad26.COV2-S | 1.70 | 1.06 | 2.64 | 0.0214 | 1.56 | 0.37 | 4.55 | 0.4733 |
Age | 0.99 | 0.98 | 1.00 | 0.0281 | 0.99 | 0.97 | 1.01 | 0.1709 |
Female | 1.61 | 1.28 | 2.02 | < 0.0001 | 1.44 | 0.81 | 2.66 | 0.2248 |
mSCQ | 1.27 | 1.20 | 1.34 | < 0.0001 | 1.26 | 1.12 | 1.40 | < 0.0001 |
Interval V-R | 1.01 | 1.00 | 1.01 | 0.1426 | 1.02 | 1.00 | 1.04 | 0.0541 |
Second vaccination (n = 9351, reference = BNT162b2 + BNT162b2)
| ||||||||
Intercept | 0.09 | 0.06 | 0.13 | < 0.0001 | 0.01 | 0.00 | 0.02 | < 0.0001 |
mRNA-1273 + mRNA-1273 | 1.14 | 0.97 | 1.34 | 0.1164 | 0.87 | 0.52 | 1.39 | 0.5793 |
ChAdOx1 + ChAdOx1 | 0.72 | 0.48 | 1.07 | 0.1130 | 0.78 | 0.25 | 2.17 | 0.6434 |
ChAdOx1 + BNT162b2 | 0.85 | 0.64 | 1.13 | 0.2711 | 0.39 | 0.16 | 0.91 | 0.0380 |
ChAdOx1 + mRNA-1273 | 0.80 | 0.57 | 1.12 | 0.2047 | 0.23 | 0.06 | 0.71 | 0.0160 |
Age | 1.00 | 0.99 | 1.0024 | 0.4154 | 1.00 | 0.99 | 1.02 | 0.5247 |
Female | 1.64 | 1.45 | 1.85 | < 0.0001 | 0.89 | 0.64 | 1.24 | 0.4714 |
mSCQ | 1.24 | 1.20 | 1.28 | < 0.0001 | 1.22 | 1.14 | 1.30 | < 0.0001 |
Interval V-R | 1.01 | 1.01 | 1.01 | < 0.0001 | 1.02 | 1.01 | 1.03 | 0.0005 |
Interval to 2nd dose | 1.00 | 1.00 | 1.01 | 0.2156 | 1.01 | 0.99 | 1.04 | 0.3703 |
Third vaccination (n = 2371, reference = PI mRNA + BNT162b2)
| ||||||||
Intercept | 0.15 | 0.10 | 0.23 | < 0.0001 | 0.01 | 0.00 | 0.03 | < 0.0001 |
PI mRNA + mRNA-1273 | 0.95 | 0.73 | 1.24 | 0.7316 | 1.12 | 0.54 | 2.33 | 0.7654 |
PI vector + BNT162b2 | 1.25 | 0.70 | 2.14 | 0.4362 | 2.62 | 0.80 | 7.32 | 0.0825 |
PI vector + mRNA-1273 | 0.44 | 0.16 | 1.01 | 0.0759 | NA* | NA* | NA* | NA* |
PI mRNA/vector + BNT162b2 | 0.77 | 0.49 | 1.16 | 0.2225 | 1.09 | 0.31 | 3.08 | 0.8780 |
PI mRNA/vector + mRNA-1273 | 0.91 | 0.59 | 1.39 | 0.6809 | 0.46 | 0.07 | 1.71 | 0.3125 |
Age | 1.00 | 0.99 | 1.00 | 0.2941 | 1.01 | 0.99 | 1.03 | 0.4204 |
Female | 1.17 | 0.93 | 1.48 | 0.1794 | 0.71 | 0.38 | 1.34 | 0.2852 |
mSCQ | 1.28 | 1.20 | 1.36 | < 0.0001 | 1.25 | 1.08 | 1.44 | 0.0018 |
Interval V-R | 1.02 | 1.01 | 1.04 | 0.0052 | 1.04 | 1.00 | 1.07 | 0.0556 |
Follow-up survey:
Doctor’s consultation
|
Follow-up survey:
Hospital care
| |||||||
First/Second vaccination (n = 9601, reference = BNT162b2 + BNT162b2)
| ||||||||
Intercept | 0.22 | 0.16 | 0.30 | < 0.0001 | 0.02 | 0.01 | 0.07 | < 0.0001 |
mRNA-1273 + mRNA-1273 | 1.08 | 0.92 | 1.25 | 0.3450 | 1.32 | 0.66 | 1.42 | 0.9261 |
ChAdOx1 + ChAdOx1 | 0.92 | 0.65 | 1.30 | 0.6490 | 0.54 | 0.39 | 2.16 | 0.9160 |
ChAdOx1 + BNT162b2 | 0.93 | 0.72 | 1.20 | 0.5850 | 0.71 | 0.27 | 1.07 | 0.0923 |
ChAdOx1 + mRNA-1273 | 0.84 | 0.61 | 1.15 | 0.2850 | 0.80 | 0.17 | 1.04 | 0.0749 |
Age | 1.00 | 0.99 | 1.00 | 0.1550 | 1.00 | 0.99 | 1.01 | 0.5637 |
Female | 1.38 | 1.24 | 1.54 | < 0.0001 | 1.59 | 0.66 | 1.12 | 0.2628 |
mSCQ | 1.26 | 1.23 | 1.30 | < 0.0001 | 1.26 | 1.14 | 1.28 | < 0.0001 |
Interval V-R | 1.01 | 1.01 | 1.01 | < 0.0001 | 1.02 | 1.01 | 1.02 | < 0.0001 |
Interval to 2nd dose | 1.00 | 0.99 | 1.00 | 0.1480 | 1.00 | 0.98 | 1.01 | 0.7033 |
Third vaccination (n = 2304, reference = PI mRNA + BNT162b2)
| ||||||||
Intercept | 0.34 | 0.25 | 0.47 | < 0.0001 | 0.01 | 0.01 | 0.03 | < 0.0001 |
PI mRNA + mRNA-1273 | 1.04 | 0.84 | 1.29 | 0.7214 | 0.75 | 0.40 | 1.38 | 0.3583 |
PI vector + BNT162b2 | 0.95 | 0.58 | 1.52 | 0.8358 | 1.14 | 0.32 | 3.11 | 0.8163 |
PI vector + mRNA-1273 | 0.79 | 0.42 | 1.43 | 0.4563 | 0.96 | 0.15 | 3.40 | 0.9615 |
PI mRNA/vector + BNT162b2 | 0.82 | 0.58 | 1.15 | 0.2562 | 1.58 | 0.69 | 3.32 | 0.2517 |
PI mRNA/vector + mRNA-1273 | 0.87 | 0.62 | 1.21 | 0.4139 | 0.62 | 0.21 | 1.55 | 0.3498 |
Age | 1.00 | 0.99 | 1.00 | 0.6220 | 1.02 | 1.00 | 1.03 | 0.0843 |
Female | 1.18 | 0.98 | 1.42 | 0.0811 | 0.89 | 0.54 | 1.49 | 0.6506 |
mSCQ | 1.19 | 1.13 | 1.26 | < 0.0001 | 1.14 | 1.00 | 1.28 | 0.0190 |
Interval V-R | 1.01 | 1.01 | 1.02 | 0.0013 | 1.01 | 1.00 | 1.03 | 0.0392 |